{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:28:21Z","timestamp":1790630901047,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jns.2025.123537","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:57:11Z","timestamp":1747061831000},"page":"123537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus"],"prefix":"10.1016","volume":"474","author":[{"given":"Nadia","family":"Zivlaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daut Can","family":"Asani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Hartwig","family":"Trier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danguol\u0117","family":"\u017diogien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Gedvilait\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa Petraityt\u0117","family":"Burneikien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaldas","family":"Ciplys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimantas","family":"Slibinskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Houen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette Lautrup","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2025.123537_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jns.2025.123537_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nri2550","article-title":"Autoimmune T cell responses in the central nervous systems","volume":"9","author":"Govermann","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jns.2025.123537_bb0015","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2025.123537_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 Revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jns.2025.123537_bb0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Simpson","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2025.123537_bb0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jns.2025.123537_bb0035","first-page":"160","article-title":"Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2025.123537_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.587078","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"11","author":"Houen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2025.123537_bb0045","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","article-title":"Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis","volume":"186","author":"Vietzen","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jns.2025.123537_bb0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jns.2025.123537_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.imlet.2023.02.003","article-title":"Antibodies to expanded virus antigen panels show elevated diagnostic sensitivities in multiple sclerosis and optic neuritis","volume":"254","author":"G\u00e5sland","year":"2023","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jns.2025.123537_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577868","article-title":"Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis","volume":"367","author":"Kyllesbech","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2025.123537_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105037","article-title":"Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy","volume":"79","author":"R\u00f8d","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123537_bb0070","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"20","author":"Tengvall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jns.2025.123537_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jns.2025.123537_bb0080","doi-asserted-by":"crossref","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jns.2025.123537_bb0085","doi-asserted-by":"crossref","first-page":"13609","DOI":"10.3390\/ijms241713609","article-title":"Antibody cross-reactivity in auto-immune diseases","volume":"24","author":"Trier","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2025.123537_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577314","article-title":"Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis","volume":"346","author":"Houen","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2025.123537_bb0095","first-page":"476","article-title":"Interaction of the viral infectious agents in the development and exacerbation of the multiple sclerosis","volume":"31","author":"Mahdavi","year":"2023","journal-title":"Infez. Med."},{"key":"10.1016\/j.jns.2025.123537_bb0100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3390\/v12060643","article-title":"Role of viruses in the pathogenesis of multiple sclerosis","volume":"12","author":"Tarlinton","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jns.2025.123537_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16387","article-title":"Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis","volume":"31","author":"Ingvarsson","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2025.123537_bb0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/ene.14597","article-title":"Epstein-Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis","volume":"28","author":"Bistr\u00f6m","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2025.123537_bb0115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1212\/WNL.58.3.471","article-title":"Multiple sclerosis\u2013associated retrovirus (MSRV) in Sardinian MS patients","volume":"58","author":"Dolei","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123537_bb0120","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.arcmed.2018.10.001","article-title":"Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis is infective in vitro","volume":"49","author":"Hern\u00e1ndez-Gonz\u00e1lez","year":"2018","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.jns.2025.123537_bb0125","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/1352458511428081","article-title":"Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis","volume":"18","author":"Simpson","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2025.123537_bb0130","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1111\/ene.14961","article-title":"Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control study","volume":"28","author":"Grut","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2025.123537_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032767","article-title":"CMV infection attenuates the disease course in a murine model of multiple sclerosis","volume":"7","author":"Pirko","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2025.123537_bb0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12974-019-1517-1","article-title":"Impact of B cells to the pathophysiology of multiple sclerosis","volume":"16","author":"Arneth","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2025.123537_bb0145","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/13524585211033190","article-title":"Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis","volume":"27","author":"Hartung","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2025.123537_bb0150","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Invited article: inhibition of B cell functions: implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123537_bb0155","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ T cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2025.123537_bb0160","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis","volume":"142","author":"von Essen","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.123537_bb0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II clinical Investigators. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2025.123537_bb0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"ORATORIO clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2025.123537_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103678","article-title":"The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: a hypothesis","volume":"59","author":"Berger","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123537_bb0180","first-page":"4","article-title":"Expression and characterisation of rubella virus capsid protein in yeast cells","volume":"3","author":"Petraityt\u0117","year":"2006","journal-title":"Biologija"},{"key":"10.1016\/j.jns.2025.123537_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12896-015-0187-z","article-title":"Production of recombinant VP1-derivedvirus-like particles from novel human polyomaviruses in yeast","volume":"15","author":"Norkiene","year":"2015","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jns.2025.123537_bb0190","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000067922","article-title":"Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae","volume":"45","author":"Sasnauskas","year":"2002","journal-title":"Intervirology"},{"key":"10.1016\/j.jns.2025.123537_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104490","article-title":"HBV and VZV seroprotection loss in MS patients under DMT","volume":"70","author":"Ladeira","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123537_bb0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2025.123537_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104497","article-title":"The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment","volume":"70","author":"Pham","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123537_bb0210","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2025.123537_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104094","article-title":"Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis","volume":"67","author":"Zivadinov","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123537_bb0220","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/901312","article-title":"Epstein-Barr virus specific antibody response in multiple sclerosis patients during 21 months of Natalizumab treatment","volume":"2015","author":"Castellazzi","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.jns.2025.123537_bb0225","doi-asserted-by":"crossref","unstructured":". K Ampofo, L. Saiman, P LaRussa, S Steinberg, P Annunziato, A Gershon. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin. Infect. Dis. 34 (2002) 774\u2013779.","DOI":"10.1086\/338959"},{"key":"10.1016\/j.jns.2025.123537_bb0230","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1212\/WNL.0b013e3182a841e4","article-title":"Canadian pediatric demyelinating disease network. Epstein-Barr virus in oral shedding of children with multiple sclerosis","volume":"81","author":"Yea","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123537_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.07.017","article-title":"Factors influencing the durability of hepatitis B vaccine responses","volume":"39","author":"Doi","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jns.2025.123537_bb0240","article-title":"Is multiple sclerosis progression associated with the HLA-DR15 haplotype?","volume":"5","author":"St\u00fcrner","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.jns.2025.123537_bb0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/gene.2011.42","article-title":"Epstein-Barr virus and multiple sclerosis: interaction with HLA","volume":"13","author":"Sundqvist","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.jns.2025.123537_bb0250","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/brain\/awae110","article-title":"Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis","volume":"147","author":"Huang","year":"2024","journal-title":"Brain"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25001546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25001546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T14:34:35Z","timestamp":1751207675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25001546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"alternative-id":["S0022510X25001546"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123537","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123537"}}